Clinical Trials
Clinical trials test new treatments to find better ways to prevent, detect or treat disease. Both healthy people and people with a disease or condition can volunteer to be part of a trial.
Cancer Care Services participate in a range of clinical trials at our hospitals. For information about any of the trials below, ask your doctor or nurse.
For information about clinical trials in general visit the Australian Clinical Trials website or search the Australia and New Zealand Clinical Trials Registry.
| Disease | Trial name | Trial description | Hospital |
|---|---|---|---|
| Acute Leukaemia | ALLG AML M21 | A phase Ib/II clinical evaluation of Ponatinib in combination with 5-azacitidine in FLT3-ITD positive acute myeloid leukaemia AML M21 | RBWH |
| Acute Leukaemia | ALLG NBCR | Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry | RBWH |
| Acute Leukaemia | ALLG AML M16 | Sorafenib in Combination with Intensive Chemotherapy for Previously Untreated Adult FLT3-ITD Positive AML: A Phase 2 Randomised Double-Blind Placebo Controlled Multi-Centre Study (ALLG AML M16) | RBWH |
| Acute Leukaemia | IDHENTIFY | A Phase 3, Multicenter, Randomized, Open-label Study of Orally Administered AG-221 Versus Conventional Care Regimens in Subjects with Isocitrate Dehydrogenase 2 Mutation Positive Acute Myeloid Leukemia Refractory to or Relapsed after First-line Therapy | RBWH |
| Advanced or Metastatic NSCLC | B9991005 | A Phase 1B/2, Open-Label, Dose-Finding Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with either Crizotinib or PF-06463922 in Patients with Advanced or Metastatic NSCLC | TPCH |
| Brain | ROAM | Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial | RBWH |
| Brain | ROAM | Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial | RBWH |
| Brain | WBRT | Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma- A randomised phase III trial. | RBWH |
| Brain | VPA | Evaluation of the role of valproate in the treatment of high grade glioma | RBWH |
| Breast | PALLAS | A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. PALbociclib CoLlaborative Adjuvant Study. ANZ 1603 / ABCSG 42 / AFT-05 / BIG 14-03. PALLAS | RBWH |
| Breast | TABITHA | Study of the clinical outcomes and analysis of anti-HER2 therapy in treatment of metastatic HER2 positive breast cancer | RBWH |
| Breast | Keynote 522 | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) | RBWH |
| Cervical | GYNAE MRI | Developing methods to allow adaptive radiotherapy for gynaecological cancers with MRI (cervix) | RBWH |
| Cervical | EMPOWER | An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator's Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma. | RBWH |
| Cervical & NSCLC | FMISO PET | Prognostic Value of Assessing Hypoxia in Tumours Using 18FMISO PET During a Course of Radiation Therapy - Proof of Concept Study | RBWH |
| cMet Positive NSCLC | CEGF816X2201C | A Phase II, Multicenter, Open-Label Study of EGF816 in Combination with Nivolumab in Adult Patients with EGFR mutated NSCLC and of INC280 in Combination with Nivolumab in Adult Patients with cMet Positive NSCLC | TPCH |
| CNS | ACED | A Phase II randomised placebo-controlled, double blind, multisite study of Acetazolamide versus placebo for management of cerebral oedema in recurrent and/or progressive High Grade Glioma requiring treatment with Dexamethasone - The ACED trial | RBWH |
| CNS | VERTU | Veliparib, Radiotherapy and Temezolomide trial in Unmethylated MGMT Glioblastoma: A Randomised Phase II study of veliparib + radiotherapy (RT) with adjuvant temozolomide (TMZ) + veliparib versus standard RT + TMZ followed by TMZ in newly diagnosed glioblastoma (GBM) with unmethylated O (6)-methylguanine-DNA methlytransferase (MGMT) | RBWH |
| Extra Cranial Oligometastatic Disease | CORE | A multi stage multi centre international randomised trial of Conventional care Or Radioablation (stereotactic body radiotherapy) for Extra-cranial oligometastatic disease in lung and breast and prostate cancer. | RBWH |
| Gastro-Oesophagaeal | INTEGRATE II | INTEGRATE II trial, a Phase III study of regorafenib in refractory advanced oesophago-gastric cancer (AOGC). | RBWH |
| Gastro-Oesophagaeal | JAVELIN GASTRIC 100 | A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction. EMR 100070-007 | RBWH |
| Genito-Urinary | PROfound | A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations | RBWH |
| Genito-Urinary | Imvigor 010 (WO29636) | A Phase III, open-label, multicenter, randomized study of Atezolizumab (Anti-PD-L1 anitbody) versus observation as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma after surgical resection | RBWH |
| Genito-Urinary | IMvigor 130 (WO30070) | The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy | RBWH |
| Genito-Urinary | UNISoN | anzUp Nivo->Ipi+Nivo Sequential Non-clear cell - Proposed Phase II Sequential Cohort Trial Of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab In Metastatic Or Unresectable Non-Clear Cell Renal Cell Carcinoma. | RBWH |
| Genito-Urinary | Checkmate CA209-9ER | A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma. | RBWH |
| Genito-Urinary | A Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration- Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (KEYNOTE-199) | ||
| Genito-Urinary | IMbassador 250 (CO39385) | A Phase III, multicenter, randomized study of atezolizumab (anti-PD-L1 antibody) in combination with enzalutamide versus enzalutamide alone in patients with metastatic castration resistant prostate cancer after failure of an androgen synthesis inhibitor and failure of, ineligibility for, or refusal of a taxane regimen CO39385 | RBWH |
| Genito-Urinary | BEP | A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for participants with intermediate and poor-risk advanced germ cell tumours. | RBWH |
| Genito-Urinary | IMmotion 010 (WO39210) | A phase III, multicentre, randomised, placebo-controlled, double-blind study of atezolizumab (anti- PD-L1 antibody) as adjuvant therapy in patients with PD-L1 selected renal cell carcinoma at intermediate to high risk of developing metastasis following nephrectomy | RBWH |
| Gynaecological | VELIA M13-694 | A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (M13-694) | RBWH |
| Gynaecological | C31004 TAKEDA Endometrial | A Phase 2 Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor) MLN0128+MLN1117 (a PI3Ka Inhibitor) Weekly Paclitaxel or the Combination of Weekly Paclitaxel and MLN0128 in women With Advanced Recurrent or Persistent Endometrial Cancer (C31004) | RBWH |
| Head and Neck | Keynote 412 | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma. MK-3475-412 | RBWH |
| Head and Neck | HPV | A randomised trial of Weekly Cetuximab And Radiation Versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma | RBWH |
| Head and Neck | JNJ Saliva Study | Developing an Oral Rinse Method to Detect Human Papillomarvirus | RBWH |
| Head and Neck | Nimoral | A blind randomized multicenter study of accelerated fractionated chemo-radiotherapy with or without the hypoxic cell radiosensitizer nimorazole (Nimoral), using a 15 gene signature for hypoxia in the treatment of squamous cell carcinoma of the head and neck | RBWH |
| Head and Neck | SPIT | A simple saliva test to diagnose head and neck cancer at an early stage - head and neck cancer detection is a spitting distance away | RBWH |
| Head and Neck | P2191 | Development of an Adoptive T Cell Therapy for HPV-Associated Malignancies | RBWH |
| Kidney | FASTRACK II | Focal Ablative Stereotactic Radiosurgery for Cancers of the Kidney - A Phase II Clinical Trial. | RBWH |
| Leukaemia | FUSION | A phase 2, international, multicenter, randomized, open-label, parallel group to evaluate the efficacy and safety of CC-486 (Oral Azacitidine) alone in combination with Durvalumab (MEDI4736) in subjects with myelodysplastic syndromes who fail to achieve an objective response to treatment with azacitidine for injection or decitabine | RBWH |
| Lower GI | ASCOLT | ASCOLT: Aspirin for Dukes C and high risk Dukes B colorectal cancers - an international, multi-centre, double blind, randomised placebo controlled phase III trial. | RBWH |
| Lower GI | cfDNA | Evaluation of temporal dynamics of RAS mutation emergence in cell free DNA (cfDNA) in response to first-line cetuximab anti-EGFR therapy in patients with metastatic colorectal cancer | RBWH |
| Lower GI | RBWH & TPCH Database | The RBWH and TPCH metastatic Colorectal Cancer database: a prospective observational cohort study examining clinical and molecular biomarkers | RBWH |
| Lower GI | TRACC | TRACC (Biogrid): Study of Clinical Outcomes and Analysis of Bevacizumab use in Metastatic Colorectal Cancer | RBWH |
| Lower GI | DYNAMIC | Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage II Colon Cancer | RBWH |
| Lower GI | CHALLENGE | A phase III study of the impact of a physical activity program on disease-free survival in patients with high risk stage II or stage III colon cancer: a randomised controlled trial | RBWH |
| Lower GI | CXCR-4 PET Rectal | A pilot study of CXCR-4 PET scanning in operable rectal cancer. | RBWH |
| Lung | NIVORAD | A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer progressing after first or second line chemotherapy (NIVORAD) | RBWH |
| Lung | P_LUNG | A randomised phase III trial of High Dose Palliative Radiotherapy (HDPRT) versus concurrent Chemotherapy HDPRT (C-HDPRT) in patients with good performance status, locally advanced / small volume metastatic NSCLC not suitable for radical chemo-radiotherapy | RBWH |
| Lungs Mets | SAFRON II | Stereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A randomised Phase II Study | RBWH |
| Malignant Mesothelioma | HQoL in Malignant Mesothelioma | An Observational Study of Health-related Quality of Life in People with Malignant Mesothelioma | TPCH |
| Mesothelioma | 1199.93 | Double blind, randomised, multicentre, phase II/III study of nintedanib with Pemetrexed/Cisplatin followed by nintedanib monotherapy Vs placebo with Pemetrexed/Cisplatin followed by placebo monotherapy for treatment of unresectable malignant pleural mesothelioma | TPCH |
| Mesothelioma | CTC 0142 / ALTG 15/003 | DREAM: A phase 2 trial of durvalumab with first line chemotherapy in mesothelioma with a safety run in | TPCH |
| Multiple Myeloma | Pentixafor PET in Multiple Myeloma | Pilot study of 68Ga-Pentixafor positron emission tomography (PET) imaging in multiple myeloma | RBWH |
| Multiple Myeloma | CANDOR | A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma | RBWH |
| Multiple Solid Tumours | Keynote 158 (BASKET) | A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Select Biomarker Positive Advanced Solid Tumors | RBWH |
| Neuroendocrine | CONTROL NETS | Phase II multi-arm, randomised open label trial of Lutetium-177 Octreotate peptide receptor radionucleotide therapy, capecitabine/temozolamide chemotherapy, or the combination in the first or second line treatment of low to intermediate grade gastroenteropancreatic neuroendocrine tumours | RBWH |
| Non-Hodgkins Lymphoma | IRiC ALLG NHL29 | A Phase II study of Ibrutinib, Rituximanb and mini-CHOP therapy in very elderly patients with newly diagnosed DLBCL | RBWH |
| Non-Hodgkins Lymphoma | VERDI 292 | A phase 2/3 multi-center study comparing Blinatumomab to standard of care in subjects with relapsed/refractory aggressive B-Cell non hodgkin lymphoma | RBWH |
| NSCLC | BR.31 | A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected NSCLC | TPCH |
| Other | P1382 | Examination of genes that control the growth and survival of blood cancers | RBWH |
| Other | FEBRILE Study | Rapid diagnostic test for identification of blood stream infection in febrile haematology patients: Pilot sample collection for test optimisation and validation | RBWH |
| Other | NOMINATOR | GENOMIC MATCHING TREATMENT FOR RARE CANCERS Feasibility of performing genomic testing of rare cancers to match the cancer to treatment. | RBWH |
| Pancreas | PURPLE | Pancreatic cancer: Understanding Routine Practice and Lifting End results (PURPLE) Registry. A Prospective Pancreatic Cancer clinical registry. | RBWH |
| Pancreas | FOLFIRINOX | Prospective evaluation of FOLFIRINOX for metastatic of locally advanced Pancreatic Cancer | RBWH |
| Pancreas | CXCR-4 PET Pancreas | Imaging the CXCR-4 Chemokine receptor with a novel PET tracer in pancreatic cancer. | RBWH |
| Phase I/Melanoma | TACTI-mel | TACTI-mel - A multicentre, open label, dose escalation Phase I study in patients with unresectable or metastatic melanoma receiving Study drug as an adjunctive therapy to anti-PD-1 therapy with pembrolizumab. | RBWH |
| Phase I/Rectal | EXENT | A Non-Randomised Open-Label Phase Ib Exploratory Study of TG02-treatment as Monotherapy or in Combination with Pembrolizumab to Assess Safety and Immune Activation in Patients with Locally Recurrent Oncogenic RAS Exon 2 Mutant Rectal Cancer | RBWH |
| Phase I/Solid Tumours | CORVUS | A Phase 1/1b, open-Label, multicentre, repeat-dose, dose-selection study of CPI-444 as single agent and in combination with Atezolizumab in patients with selected incurable cancers | RBWH |
| Prostate | ENZARAD | Randomised phase III trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer. | RBWH |
| Prostate | SPLIT-COURSE | A single arm, prospective Phase II study of Split-Course Pelvic Radiotherapy for Locally Progressive, Castrate Resistant Prostate Cancer | RBWH |
| Skin | Keynote 629 | A Phase II, Open-Labelled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma MK3475-629 | RBWH |
| Skin | R28ONC1540 | A Phase 2 study of REGN2810, a fully human monoclonal anitbody to programmed death - 1 (PD1), in patients with advanced cutaneous squamous cell carcinoma. (R2810ONC1540) | RBWH |
| Small cell lung cancer | GO30081 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB (Anti?pd-l1 antibody) IN patients with UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER | TPCH |
| Thyroid | Exelixis Thyroid | A Phase 4, Randomized, Double-blind Study To Evaluate the Safety and Efficacy of Cabozantinib (XL184) at 60 And 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients | RBWH |
| Thyroid | Eisai Thyroid Phase II | A multicenter, randomized, double-blind Phase 2 Trial of Lenvatinib (E7080) in subjects with 131I-Refractory Differentiated Thyroid Cancer to evaluate whether an oral starting dose of 20 mg or 14 mg daily will provide comparable efficacy to a 24-mg starting dose, but have a better safety profile. | RBWH |
| Transplant | Treg Apheresis | Developing a method to generate regulatory T cells from healthy donors | RBWH |
| Transplant | GE180 PET GVHD Study | Pilot study of positron emission tomography (PET), using the novel TSPO-specific radiotracer 18FGE-180, to assess acute gastrointestinal graft versus host disease (GVHD) in patients undergoing allogeneic haematopoietic progenitor cell transplantation (HPCT) for haematological malignancy | RBWH |
| Transplant | REACH 2 | A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-resistant acute graft vs. host disease after allogenic stem cell transplantation | RBWH |
| Transplant | PCYC 1140 INTEGRATE | A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease(cGVHD) | RBWH |
| Transplant | IR AUTO | Observational study of immune reconstitution in patients undergoing autologous stem cell transplantation. | RBWH |
| Transplant | IR ALLO | Observational study of immune reconstitution following stem cell transplantation | RBWH |
| Transplant | IMPECT | The psychosocial impact of donating haematopoietic stem cells on adult sibling donors | RBWH |
| Transplant | IL-17 | Observational study of IL-17-related cytokines in stem cell transplantation. | RBWH |
| Upper GI | ACTICCA-1 | Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial) | RBWH |